|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of CARD15,DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases显示文摘AIM: To investigate the contribution of variants of CARD15, OCTN1/2 and DLG5 genes in disease predispo- sition and phenotypes in a large Italian cohort of pediatric patients with inflammatory bowel diseases (IBD). METHODS: Two hundred patients with Crohn’s disease (CD), 186 ulcerative colitis (UC) patients, 434 par- ents (217 trios), and 347 healthy controls (HC) were studied. Polymorphisms of the three major variants of CARD15, 1672C/T and -207G/C SNPs for OCTN genes, IGR2096a_1 and IGR2198a_1 SNPs for the IBD5 locus, and 113G/A variant of the DLG5 gene were evaluated. Potential correlations with clinical sub-phenotypes were investigated. RESULTS: Polymorphisms of CARD15 were significantly associated with CD, and at least one variant was found in 38% of patients (15% in HC, OR = 2.7, P < 0.001). Homozygosis for both OCTN1/2 variants was more com- mon in CD patients (1672TT 24%, -207CC 29%) than in HC (16% and 21%, respectively; P = 0.03), with an in- creased frequency of the TC haplotype (44.8% vs 38.3% in HC, P = 0.04). No association with the DLG5 variant was found. CD carriers of OCTN1/2 and DLG5 variants more frequently had penetrating disease (P = 0.04 and P = 0.01), while carriers of CARD15 more frequently had ileal localization (P = 0.03). No gene-gene interaction was found. In UC patients, the TC haplotype was morefrequent (45.4%, P = 0.03), but no genotype/phenotype correlation was observed. CONCLUSION: Polymorphisms of CARD15 and OCTN genes, but not DLG5 are associated with pediatric on- set of CD. Polymorphisms of CARD15, OCTN, and DLG5 genes exert a weak influence on CD phenotype. | S Cucchiara A Latiano O Palmieri AM Staiano R D'Incà G Guariso G Vieni V Rutigliano O Borrelli MR Valvano V Annese | 2007 | World Journal of Gastroenterology2007，13，8： | 9 |
| 2 | European evidence based consensus for endoscopy in inflammatory bowel disease显示文摘 | Vito Annese Marco Daperno Matthew D. Rutter Aurelien Amiot Peter Bossuyt James East Marc Ferrante Martin G?tz Konstantinos H. Katsanos Ralf Kie?lich Ingrid Ordás Alessandro Repici Bruno Rosa Shaji Sebastian Torsten Kucharzik Rami Eliakim | 2013 | Journal of Crohn’s and Colitis2013，，12： | 7 |
| 3 | Usefulness of ω-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: A double-blind, randomized, placebo-controlled study显示文摘AIM: To assess the value of long-chain ω-3 fatty acids (FAs) supplementation in addition to amino-salicylic-acid (5-ASA) in pediatric patients with Crohn's disease (CD).METHODS: Thirty-eight patients (20 males and 18females, mean age 10.13 years, range 5-16 years)with CD in remission were randomized into two groups and treated for 12 mo. Group Ⅰ (18 patients) received 5-ASA (50 mg/kg/d)+ω-3 FAs as triglycerides in gastroresistant capsules, 3 g/d (eicosapentanoic acid, EPA, 400mg/g, docosahexaenoic acid, DHA, 200 mg/g). Group Ⅱ (20 patients) received 5-ASA (50 mg/kg/d)+olive oil placebo capsules. Patients were evaluated for fatty acid incorporation in red blood cell membranes by gas chromatography at baseline 6 and 12 mo after the treatment.RESUJLTS: The number of patients who relapsed at 1year was significantly lower in group Ⅰ than in group Ⅱ(P<0.001). Patients in group Ⅰ had a significant increase in the incorporation of EPA and DHA (P<0.001) and a decrease in the presence of arachidonic acids.CONCLUSION: Enteric-coated ω-3 FAs in addition to treatment with 5-ASA are effective in maintaining remission of pediatric CD. | C Romano S Cucchiara A Barabino V Annese C Sferlazzas SIGENP Italian Study Group of Pediatric Inflammatory Bowel Diseases | 2005 | World Journal of Gastroenterology2005，11，45： | 4 |
| 4 | First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases:A 2020 Delphi consensus显示文摘Ulcerative colitis and Crohn’s disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract.The incidence and prevalence are on the rise worldwide,and the heterogeneity between patients and within individuals over time is striking.The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients.This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence-and expert opinion-based recommendations.Comprehensive up-to-date guidance is provided regarding diagnosis,evaluation of disease severity,appropriate and timely use of different investigations,choice of appropriate therapy for induction and remission phase according to disease severity,and management of main complications. | Maryam Alkhatry Ahmad Al-Rifai Vito Annese Filippos Georgopoulos Ahmad N Jazzar Ahmed M Khassouan Zaher Koutoubi Rahul Nathwani Mazen S Taha Jimmy K Limdi | 2020 | World Journal of Gastroenterology2020，26，43： | 2 |
| 5 | General and specific factors associated with severity of cognitive impairment in systemic lupus er- ythematosus 显示文摘 | Tomietto P Annese V Dagostini S | 2007 | Arthritis Rheum2007，57，： | 1 |
| 6 | Chronic in- flammatory diseases: do immunological patterns drive the choice of biotechnology drugs? 显示文摘 | SOZZANI S ABBRACCHIO MP ANNESE V | 2014 | A Crit Rev Autoimmun2014，47，5： | 1 |
| 7 | Seamless connectivity and routing in vehicular networks with infrastructure显示文摘 | ANNESE S CASETrI C CHIASSERINI C | 2011 | Vehicular Communications and Networks2011，29，3： | 1 |
| 8 | Seamless Connectivity and Routing in Vehicular Networks with Infrastructure显示文摘 | ANNESE S CA5ETTI C CHIASSERINI C | 2011 | IEEE Journal on Selected Areas in Communications2011，29，3： | 1 |
| 9 | CEP- 1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons 显示文摘 | Borasio G D Horstmann S Anneser J M H | 1998 | Neuroreport1998，9，： | 1 |
| 10 | Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis显示文摘 | Tomietto P D'Agostini S Annese V | 2007 | J Rheumatol2007，34，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员